Combinatorial miRNA signature curbs tumor growth in aggressive cancers New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug design. Written byAndrea Corona

Combinatorial miRNA signature curbs tumor growth in aggressive cancers New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug design. Written byAndrea Corona https://www.drugdiscoverynews.com/combinatorial-mirna-signature-curbs-tumor-growth-in-aggressive-cancers-17555 A team at Université Paris Cité has spent six years chasing an unusual observation: Tiny particles released by certain breast cancer cells seemed to make aggressive tumors behave less aggressively. Their new study, published in Molecular Therapy, identifies what's inside those particles that does the work, and offers a possible blueprint for building RNA-based cancer drugs around combinations of molecules rather than single targets. The story started in 2020, when the group, led by molecular biologist Sébastien Jauliac, reported that extracellular vesicles (EVs) released by breast cancer cells expressing a transcription factor called NFAT3 could reduce invasion and metastasis in aggressive cancer models. That raised an obvious follow-up question: what was actually inside those vesicles doing the work?